Category Press Releases

EC Approves Henlius and Organon’s Denosumab Biosimilars BILDYOS® and BILPREVDA®

European Commission Grants Approval for Henlius and Organon’s Denosumab Biosimilars BILDYOS® and BILPREVDA® Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced a significant regulatory milestone with the news that the European Commission (EC) has granted marketing authorization for…

Read MoreEC Approves Henlius and Organon’s Denosumab Biosimilars BILDYOS® and BILPREVDA®
MindMed

MindMed Study at Psych Congress 2025 Links GAD to High Suicidal Ideation

MindMed Presents Alarming Data on Suicidal Ideation Among Adults with Generalized Anxiety Disorder at Psych Congress 2025 Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company pioneering the development of novel product candidates for brain health…

Read MoreMindMed Study at Psych Congress 2025 Links GAD to High Suicidal Ideation
Bayer

Celltrion Launches Omlyclo™ Commercially Across Europe at EADV 2025

Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 2025 Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress,…

Read MoreCelltrion Launches Omlyclo™ Commercially Across Europe at EADV 2025

Cytokinetics Plans $550 Million Private Placement of Convertible Senior Notes

Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes  Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of convertible senior notes due…

Read MoreCytokinetics Plans $550 Million Private Placement of Convertible Senior Notes

Cytokinetics Prices $650M Upsized Convertible Notes to Refinance 2027 Debt

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior…

Read MoreCytokinetics Prices $650M Upsized Convertible Notes to Refinance 2027 Debt

Zoetis Gets CVMP Nod for Portela® (relfovetmab) to Ease Osteoarthritis Pain in Cats

Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cat Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending…

Read MoreZoetis Gets CVMP Nod for Portela® (relfovetmab) to Ease Osteoarthritis Pain in Cats

QIAGEN Achieves CE-IVDR Certification for Entire QIAstat-Dx Diagnostic Portfolio in Europe

QIAGEN Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Expands Diagnostic Leadership with Enhanced Meningitis/Encephalitis Panel QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced a significant regulatory milestone: the company has secured CE-IVDR certification for its entire QIAstat-Dx syndromic…

Read MoreQIAGEN Achieves CE-IVDR Certification for Entire QIAstat-Dx Diagnostic Portfolio in Europe

Avanzanite Bioscience Appoints Dr. Mark Bechter as Senior Vice President of Medical Affairs

Avanzanite Bioscience Strengthens Leadership with Appointment of Dr. Mark Bechter as Senior Vice President of Medical Affairs Avanzanite Bioscience B.V., a rapidly expanding European specialty pharmaceutical company dedicated to improving the lives of patients with rare diseases, announced today the…

Read MoreAvanzanite Bioscience Appoints Dr. Mark Bechter as Senior Vice President of Medical Affairs
Nuvig Therapeutics

Nuvig Therapeutics Names David Woodhouse CEO, James Mackay Board Chair

Nuvig Therapeutics Strengthens Leadership Team with Appointment of David J. Woodhouse, Ph.D., as Chief Executive Officer and James Mackay, Ph.D., as Independent Board Chair Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company dedicated to developing transformative immunomodulatory therapeutics for…

Read MoreNuvig Therapeutics Names David Woodhouse CEO, James Mackay Board Chair